Growth Metrics

Pfizer (PFE) Profit After Tax Growth (3y) (2012 - 2026)

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) PAT Growth (3y) (Qtr)
1 Novartis Ag 107,124,802.25 Bn 107,124,802.25 Bn - -
2 Eli Lilly 969.00 Bn 963.72 Bn 16.22 Bn 76.51%
3 Johnson & Johnson 539.46 Bn 517.41 Bn 15.96 Bn 133.08%
4 AbbVie 376.92 Bn 367.57 Bn 10.78 Bn 42.47%
5 Merck 285.00 Bn 279.35 Bn 12.09 Bn -51.87%
6 Amgen 177.58 Bn 165.55 Bn 5.87 Bn -13.81%
7 Gilead Sciences 163.22 Bn 155.50 Bn 5.52 Bn 26.01%
8 Pfizer 145.86 Bn 133.09 Bn -1.21 Bn 75.17%
9 Bristol Myers Squibb 111.90 Bn 101.44 Bn 8.07 Bn 712.11%
10 Gsk 88.34 Bn 83.66 Bn - -

Historic Data

Download Data 🔒
DateValue
Mar 29, 2026 75.17%
Dec 31, 2025 -109.94%
Sep 28, 2025 -25.67%
Jun 29, 2025 -33.54%
Mar 30, 2025 -27.74%
Sep 29, 2024 -18.20%
Jun 30, 2024 -80.84%
Mar 31, 2024 -13.81%
Dec 31, 2023 -36.38%
Oct 1, 2023 -53.57%
Jul 2, 2023 -47.26%
Apr 2, 2023 -46.89%
Dec 31, 2022 69.75%
Oct 2, 2022 284.57%
Jul 3, 2022 25.23%
Apr 3, 2022 26.51%
Dec 31, 2021 27.55%
Oct 3, 2021 25.75%
Jul 4, 2021 14.51%
Apr 4, 2021 11.02%
Dec 31, 2020 -73.36%
Sep 27, 2020 -19.90%
Jun 28, 2020 -5.35%
Mar 29, 2020 2.53%
Dec 31, 2019 -60.70%
Sep 29, 2019 -51.77%
Jun 30, 2019 34.76%
Mar 31, 2019 8.53%
Dec 31, 2018 -240.54%
Sep 30, 2018 24.42%
Jul 1, 2018 13.89%
Apr 1, 2018 14.47%
Dec 31, 2017 118.57%
Oct 1, 2017 2.22%
Jul 2, 2017 1.79%
Apr 2, 2017 10.25%
Dec 31, 2016 -32.86%
Oct 2, 2016 -19.52%
Jul 3, 2016 -16.68%
Apr 3, 2016 3.38%
Dec 31, 2015 -31.31%
Sep 27, 2015 -10.62%
Jun 28, 2015 -6.96%
Mar 29, 2015 9.90%
Dec 31, 2014 51.99%
Sep 28, 2014 -10.54%
Jun 29, 2014 4.92%
Mar 30, 2014 1.58%
Dec 31, 2013 -5.32%
Sep 29, 2013 44.80%
Jun 30, 2013 12.93%
Mar 31, 2013 10.72%
Dec 31, 2012 -0.89%
Sep 30, 2012 1.19%
Jul 1, 2012 12.97%
Apr 1, 2012 -13.06%